Reference
- Lane KAG. Pulmonary disorders. In: Beers MH, Berkow R, editors. The Merck Manual, 17th edn. West Point: The Merck & Co., Inc., 1999: 601–602
- Samsa GP, Matchar DB, Harnett J, Wilson J. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP IN trial. Chest 2005;128:3246-3254
- American Thoracic. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am J Resp Crit Care Med 2001;163:1730-1754
- Wiblin RT, Wenzel RP. Hospital-acquired pneumonia. Curr Clin Top Infect Dis 1996;16:194-214
- Hong Kong Hospital Authority Statistical Report 2005–2006.
- Inter-hospital Multi-Disciplinary Programme on Antimicrobial ChemoTherapy (IMPACT), 3rd edn (version 3.0). Hong Kong Hospital Authority, 2005
- Shea-Lewis A. Cost analysis in the healthcare arena. Available at: http://www.continuingeducation.com/nursing/costanalysis/index.html. Last accessed May 2001
- Hong Kong Hospital Authority Annual Report 2006–2007.
- Petrie A, Sabin C. Medical Statistics at a Glance, 2nd edn. Malden, MA: Blackwell Publishing, 2005
- Peat J, Barton B. Medical Statistics: a Guide to Data Analysis and Critical Appraisal. Malden, MA. Blackwell Publishing, 2005
- Hong Kong, Hospital Authority. G.N. (S.) 44 of 2003 (list of charges, sections 18 (1) and 18 (2), Hong Kong Hospital Authority ordinance), gazette number 13/2003, special supplement No. 4. The Government of the Hong Kong Special Administrative Region, 2003
- Guglielmo BJ, Dudas V, Tran S, et al. Treatment outcomes associated with community-acquired pneumonia in US hospitals: a 3000 patient survey. Ann Pharmacother 2000;34;446-452
- Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001;119:1439-1448
- Vardakas KZ, Siempos II, Grammatikos A, et al. Respiratory fluoroquinolones for the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials. CMAJ 2008;179:1269-1277
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2): S27-72
- Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995;333:1618-1624
- Loeb MB. Community-acquired pneumonia in older people: the need for broader perspective. J Am Geriatr Soc 2003;51:539-543
- Koda-Kimble MA, Young LY, Kradjan WA, et al. Applied Therapeutics – the Clinical Use of Drugs, 7th edn. Lippincott Williams & Wilkins, 2001
- Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002;347:2039-2045